Efficacy and safety of T-DXd in patients with HER2-positive and HER2-low metastatic breast cancer: a real-world study
{{output}}
Background: The DESTINY-Breast trials established trastuzumab deruxtecan (T-DXd) as a treatment significantly improving outcomes in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low metastatic breast cancer (M... ...
